Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
CAPR Stock Chart & Stats
$27.81
-$0.36(-2.53%)
At close: 4:00 PM EST
$27.81
-$0.36(-2.53%)
Day’s Range― - ―
52-Week Range$4.30 - $40.37
Previous CloseN/A
Volume187.65K
Average Volume (3M)4.43M
Market Cap
$1.51B
Enterprise Value$248.97M
Total Cash (Recent Filing)$98.57M
Total Debt (Recent Filing)$14.54M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Mar 25, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding54,400,784
10 Day Avg. Volume1,975,774
30 Day Avg. Volume4,434,605
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)3.34
Price to Sales (P/S)21.82
P/FCF Ratio-11.70
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue22.37
Enterprise Value/Gross Profit-3.85
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$48.75Price Target Upside75.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.13
Revenue Forecast (FY)$737.50K
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationsAnalyst recommends buying Capricor Therapeutics stock and has raised the price target to $50.
Clinical Trial SuccessCapricor announced top-line data from the HOPE-3 trial for Deramiocel in Duchenne muscular dystrophy, meeting both the primary and key secondary endpoints, leading to a sharp increase in CAPR shares.
Regulatory ProgressCapricor's plan to submit HOPE-3 data aims to secure a label encompassing both cardiac and skeletal muscle function in DMD.
Bears Say
Market VolatilityCAPR's shares are likely going to be volatile ahead of the data as investors try to align with the potential for FDA-stated flexibility around the 'totality of the data'.
Stock Price ConcernsCAPR shares currently are near the CRL-lows as investors await the top-line data.
Uncertainty In Regulatory PathThe bear case would be the path forward is just too unsure from here and definitive FDA feedback would be needed.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $4.30 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $1.51B.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 92 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.007.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 54,400,784 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went up 11.511%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.75 (75.30% Upside)
$48.75 (75.30% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 231.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.58%
12-Months-Change
Fundamentals
Return on Equity
-107.79%
Trailing 12-Months
Asset Growth
36.03%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics (CAPR) is a biotechnology company focused on developing innovative therapies for diseases with significant unmet medical needs. The company primarily operates in the regenerative medicine sector, leveraging its proprietary technology platforms to create treatments aimed at cardiovascular diseases and other conditions. Capricor's core products include its lead investigational therapies that utilize exosome-based delivery systems, which are designed to enhance tissue repair and regeneration.
CAPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the clinical development of Daramycin and operational readiness for commercialization. However, financial challenges were evident with zero revenue in 2025 and increased operating expenses, alongside the need to address regulatory hurdles following a CRL.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$48.75
▲(75.30% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
5.80% Mutual Funds
6.60% Other Institutional Investors
79.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---